ReviewThe American journal of gastroenterology2018
Discontinuing Long-Term PPI Therapy: Why, With Whom, and How?
Review in The American journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Identification of Potentially Inappropriate Medications for Adults Below 65 Years: Protocol for a Modified Delphi Study.JMIR research protocols · 2026Article
- Appropriate prescribing and deprescribing of proton pump inhibitors: New Choosing Wisely Canada toolkit.Canadian family physician Medecin de famille canadien · 2026Article
- Dynamic precision therapy in chronic gastrointestinal diseases: A focus on gastroesophageal reflux disease and inflammatory bowel disease-A narrative review and conceptual perspective.Therapeutic advances in gastroenterology · 2026Review
- Exploring the etiology of colitis: insights from gut microbiota research.Gut microbes · 2025Review
- Economic and treatment burden among newly diagnosed patients with erosive esophagitis in the US: a national retrospective cohort study.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025Article
- Integrated models of population pharmacokinetics and exposure response to optimize dosage regimen for anaprazole sodium in duodenal ulcer.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2024Article
- Effects of proton pump inhibitors on inflammatory bowel disease: An updated review.World journal of gastroenterology · 2024Review
- Prescribing Portraits to Optimize Prescribing of Proton Pump Inhibitors in Long-Term Care: PPI-T STOP Study.The Canadian journal of hospital pharmacy · 2024Article
- Influence of proton pump inhibitor use on clinical outcomes of patients with inflammatory bowel disease.Annals of medicine · 2023Article
- Comparison of the prevalence and nature of potentially inappropriate medication use in geriatric outpatients between tertiary and community healthcare settings: a multicenter cross-sectional study.International journal of clinical pharmacy · 2022Article
- Risk of Pyogenic Liver Abscess in Proton Pump Inhibitor Users: New Inventory of Proton Pump Inhibitor Induced Complications?Journal of neurogastroenterology and motility · 2021Article
- Reflux Symptoms: Functional and Structural Diseases and the Approach from the GI Specialist.Digestive diseases (Basel, Switzerland) · 2021Article
- Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development.BMC cancer · 2020Article
- Physicians' Perceptions of Proton Pump Inhibitor Risks and Recommendations to Discontinue: A National Survey.The American journal of gastroenterology · 2020Article
- The Dark Side of the Long-Term Use of Proton Pump Inhibitors in Chronic Liver Disease.GE Portuguese journal of gastroenterology · 2019Article
- PPI Long Term Use: Risk of Neurological Adverse Events?Frontiers in neurology · 2018Review
- The Medical Management of Gastroesophageal Reflux Disease: A Narrative Review.Journal of primary care & community healthReview
- Multidisciplinary Consensus for Rationalizing the Use of Acid Suppressants in Children and Adults: CONFOR.Euroasian journal of hepato-gastroenterologyReview
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton pump inhibitors (PPIs) are among the most widely used class of drugs prescribed over the long term in all of clinical medicine with 8-10% of ambulatory adults have been prescribed a PPI in the past 30 days. However, numerous studies have raised doubts about the long term safety of PPI use. The purpose of this review is threefold: (i) To provide an overview of the current evidence demonstrating associations between PPI use and adverse health outcomes and the likelihood of the associations being causal (Why?); (ii) To be able to identify long-term PPI users in whom the intensity of PPI therapy could be reduced or in whom PPIs could be eliminated outright (Who?); and (iii) To provide strategies on how to reduce or stop chronic PPI therapy while maintaining symptom control and reducing the risk for symptom or upper GI disease recurrence (How?).
Indexed as
Identifiers
29557943What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.